JBJulia Berger

Julia Berger

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Julia Berger has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Generation of a fully infectious SARS-CoV-2 encoding an internally tagged nsp3

    by Liana Uebler, Maximilian Sandmann, Neele Pekarek, Julia Berger, Marc Lütgehetmann, Björn-Philipp Diercks, Ronald von Possel, Petra Emmerich, Ralf Fliegert, Susanne Pfefferle

    The analysis of coronavirus replicase proteins during authentic infection is experimentally challenging, particularly for large and essential components embedded within virus-induced replication organelles. Non-structural protein 3 (nsp3), the largest coronavirus replicase protein, plays a central role in replication organelle formation, but has remained difficult to genetically manipulate. Here, we generated a fully infectious recombinant SARS-CoV-2 encoding an internal ALFA epitope tag upstream of the Mac1 domain within nsp3 (rALFA). Growth kinetics analyses demonstrated that rALFA replicated with kinetics and peak titers comparable to those of untagged recombinant SARS-CoV-2, and retained lytic infection. Tagged nsp3 displayed subcellular localization patterns equal to those observed in infections with untagged virus, and nanobody-based detection enabled robust visualization of nsp3 in infected cells. This internally tagged SARS-CoV-2 establishes a useful experimental platform for future analyses of nsp3 localization and replication organelle dynamics under authentic infection conditions, and provides a foundation for subsequent functional studies. IMPORTANCE: The manuscript presents a practical tool that advances coronavirus methodology.

  • Open Access

    Publisher Correction: Design, structure-based optimization and antiviral evaluation of potent inhibitors for the macrodomain Mac1 of SARS-CoV-2

    by Maximilian Sandmann, Sahra Tajdar, Simon Sander, David Ruiz Carrillo, Benedikt Ganter, Celine Fischer, Marina Ocenas, Stefanie Etzold, Neele Pekarek, Julia Berger, et al.

  • Open Access

    Publisher Correction: Design, structure-based optimization and antiviral evaluation of potent inhibitors for the macrodomain Mac1 of SARS-CoV-2

    by Maximilian Sandmann, Sahra Tajdar, Simon Sander, David Ruiz Carrillo, Benedikt Ganter, Celine Fischer, Marina Ocenas, Stefanie Etzold, Neele Pekarek, Julia Berger, et al.

  • Open Access

    Variant-specific nucleocapsid mutations shape host innate immune trajectories during SARS- CoV-2 infection

    by Julia M. Berger, Jonas Schröder, Timothy K. Soh, Neele Pekarek, Lara- Marie Breul, Simon Dörner, Patrick Blümke, Jiabin Huang, Jens B. Bosse, Susanne Pfefferle, et al.

    The SARS-CoV-2 nucleocapsid (N) protein is one of the most highly expressed proteins during infection and plays crucial roles in the protection and packaging of viral RNA, replication, suppression of the immune response and virus assembly. The N gene and the overlapping accessory open reading frame ORF9b have continually evolved throughout the circulation of the virus, likely due to ongoing adaptation to the human host. This genetic variability influences the interplay of the N protein and its interactors. Yet, little is known about how specific mutations within the N/ORF9b locus of Variants of Concern (VOCs) shape the progression and outcome of infection. Here, we use a multi-omics approach to decipher how these genetic alterations reprogram the host cell by creating Wuhan-Hu-1-based recombinant viruses carrying an isogenic backbone with respective N mutations from the VOCs (called rNs) and comparing their effects at the transcriptome and proteome levels. We found that the mutations induce distinct transcriptional and translational alterations: rN-Alpha drives a stealth-like infection characterized by sustained translation efficiency and specific evasion of the 2’-5’-oligoadenylate synthetase (OAS) innate immune sensor, whereas rN-Delta and rN-BA.2 trigger a highly elevated inflammatory response. For rN-Delta, hyperphosphorylation of the N-protein drives cellular stress culminating in necroptotic cell death. Because these viruses differ only within the N/ORF9b locus, N sequence variation emerges as a determinant of infection outcome in its own right, warranting increased surveillance attention.

  • Open Access

    Design, structure-based optimization and antiviral evaluation of potent inhibitors for the macrodomain Mac1 of SARS-CoV-2

    by Maximilian Sandmann, Sahra Tajdar, Simon Sander, David Ruiz Carrillo, Benedikt Ganter, Celine Fischer, Marina Ocenas, Stefanie Etzold, Neele Pekarek, Julia Berger, et al.

    Enzymatically active macrodomains of (+)ss-RNA viruses mediate immune evasion by countering ADP-ribosylation and are therefore promising druggable targets. Here we report testing of ADP / ADP-ribose analogues for their ability to inhibit Mac1 of SARS-CoV-2, measurement of the affinity of active compounds and characterization of their binding mode by cocrystallization, uncovering critical molecular determinants of protein-ligand interaction. Key findings of the resulting structure-activity relationship (SAR) include that inhibitory potency is improved by either replacing the distal ribose of ADP-ribose by a small alkyl group or the adenine N7 by carbon. Based on insights from the SAR, we show β-methyl-GS-441524-diphosphate as nanomolar inhibitor that exhibits >1000-fold selectivity over human MacroD1 and MacroD2. Addition of C 11 -acyloxybenzyl (AB)-masking groups yields a membrane permeable, lipophilic prodrug that inhibits SARS-CoV-2 in cell culture (EC 50 0.06 µM) while exhibiting low cytotoxicity (CC 50 > 50 µM). Replacement of the terminal methyl phosphate with an ethyl phosphonate increases stability of the prodrug with little effect on toxicity and antiviral potency (EC 50 = 0.03 µM), making it a membrane-permeable nucleotide-based prodrug against viral macrodomains.